| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Metacrine, Inc. | Chief Business Officer | Common Stock | 103,499 | $48,645 | $0.4700 | 26 Jan 2023 | Direct |
| Metacrine, Inc. | Chief Business Officer | Stock option (right to buy) | 210,553 | 27 Feb 2022 | Direct | ||
| PhaseBio Pharmaceuticals Inc | VP, Corporate Development | Common Stock | 7,059 | 20 May 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000120919123005275-york-michael-2023-01-26 | Metacrine, Inc. | 26 Jan 2023 | 1 | -$44,331 | 4 | Chief Business Officer | 27 Jan 2023, 15:44 |
| /report/000120919122014077-york-michael-2022-02-27 | Metacrine, Inc. | 27 Feb 2022 | 2 | $0 | 4 | Chief Business Officer | 01 Mar 2022, 15:55 |
| /report/000120919122012734-york-michael-2022-02-18 | Metacrine, Inc. | 18 Feb 2022 | 0 | $0 | 3 | Chief Business Officer | 24 Feb 2022, 15:52 |
| /report/000116924521000044-york-michael-2021-05-20 | PhaseBio Pharmaceuticals Inc | 20 May 2021 | 1 | +$8,112 | 4 | VP, Corporate Development | 24 May 2021, 18:10 |